scorecardresearch
Add as a preferred source on Google
Monday, November 17, 2025
TopicAlzheimer

Topic: Alzheimer

How semaglutide is emerging as A-Z drug, helping with diabetes, alcohol cravings & more

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.

There is a huge treatment gap for neurological conditions like Alzheimer’s—how to close it

Health inequities compound the problem, with people living in rural or poor communities disproportionately affected. The coverage of publicly funded medicines needs to be improved.

How a protein fragment in the brain & spinal fluid may simplify tracking Alzheimer’s progression

Researchers have identified a fragment of tau protein called MTBR-tau243. Tracking it, instead of the entire protein, may make monitoring Alzheimer's easier & less dependent on complex imaging.

Alzheimer’s can be diagnosed as early as 30—and symptoms aren’t what you’d expect

Those living with young-onset Alzheimer’s disease show more rapid – and aggressive – changes in their brain.

Alzheimer was a doctor who discovered a ‘special illness’ in his 50-year-old German patient

In ‘My Father’s Brain’, Sandeep Jauhar recounts his parent’s experience with Alzheimer’s while delving into the history – and fallout – of the disease.

‘Rare’ genetic mutation linked to Alzhiemer’s resistance in international study 

In study published in 'Nature Medicine' Monday, researchers from Colombia, Germany, & US cite case of a 67-yr-old whose cognition remained intact despite having genetic markers for Alzheimer's.

New Alzheimer’s drug Lecanemab shows promising results, but raises several questions

While lecanemab saw less decline in cognition and function of patients, the drug is effective only at a very early stage -- closer to the onset of the disease.

More accurate way to predict who will develop Alzheimer’s disease – new study

With the fast progression of research in biomarkers, we are quickly getting better at measuring and detecting early signs of Alzheimer’s.

Why US approval of Alzheimer’s drug has divided doctors over its effectiveness & uses

Despite the divide, having the drug on the market will change Alzheimer’s care, at least for some patients, and the FDA’s green light might pave the way for future therapies.

Why this woman in Colombia didn’t develop Alzheimer’s despite being at great risk for it

ScientiFix, our weekly feature, offers you a summary of the top global science stories of the week, with links to the best sources to read them.

On Camera

What Pakistan Supreme Court judge Mansoor Ali Shah wrote in his resignation letter

The recent resignations of its seniormost judges are among the most pointed institutional protests Pakistan has witnessed since the lawyers’ movement of the late 2000s.

As govt starts rolling back Quality Control Orders, a look at adverse impact they had, mainly on MSMEs

Between 2016 and 2025, around 700 QCOs were issued by the government. Now, it has withdrawn 69 of them.

Drone manufacturer ideaForge wins orders worth over Rs 100 crore from Army

ideaForge has formed a joint venture to manufacture and market UAVs in the US. Its Q6 UAV is now included in NATO and allied procurement systems.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.